The functional significance of chronotropic incompetence during dobutamine stress test

A Elhendy, R T van Domburg, J J Bax, P R Nierop, M L Geleijnse, M M Ibrahim, J R T C Roelandt

Abstract

Objective—To investigate the functional significance of chronotropic incompetence during dobutamine stress echocardiography.

Patients and methods—The functional significance of chronotropic incompetence was evaluated during dobutamine stress echocardiography in 512 patients without β blocker treatment who underwent dobutamine stress echocardiography (up to 40 µg/kg/min) and completed the protocol or reached the target heart rate. Mean (SD) age was 60 (12) years (313 men, 199 women). Chronotropic incompetence was defined as failure to achieve 85% of the maximum exercise heart rate predicted for age and sex (220 − age in men; 200 − age in women) at maximum dobutamine dose.

Results—Chronotropic incompetence occurred in 196 patients (38%). Affected patients were significantly younger, more likely to be men (both p << 0.001) and smokers (p < 0.05), had a higher prevalence of previous myocardial infarction (p < 0.005) and resting wall motion abnormalities (p < 0.05), and had a lower resting heart rate (p << 0.001) and systolic blood pressure (p << 0.001) than patients without chronotropic incompetence, but there was no difference in the overall prevalence of ischaemia and significant coronary artery disease. By multivariate analysis, independent predictors of chronotropic incompetence were a lower resting heart rate (p << 0.001), younger age (p << 0.001), and male sex (p << 0.001).

Conclusions—The relations among sex, age, and chronotropic incompetence show the need to titrate the dobutamine dose using specific data based on age and sex related heart rate responses to dobutamine rather than to an exercise stress test. Obtaining specific heart rate criteria is necessary to determine whether chronotropic incompetence represents a real failure to achieve a normal response or is the result of applying an inappropriate gold standard.

(Heart 1999;81:398–403)

Keywords: dobutamine; echocardiography; chronotropic incompetence

Chronotropic incompetence during exercise stress test has been recognised as a predictor of increased mortality and of coronary heart disease. Pharmacological stress testing using high dose dobutamine results in an increase in heart rate and myocardial contractility; the dobutamine stress test is therefore considered to be an exercise simulator suitable for evaluating patients with known or suspected coronary artery disease. Some patients, however, fail to reach an adequate heart rate despite the maximum dose of dobutamine, even in absence of concurrent β blocker treatment. Despite the known association between chronotropic incompetence during exercise stress testing and the risk of coronary artery disease, the functional significance of the impaired chronotropic response to dobutamine has not been evaluated. The identification of variables associated with chronotropic incompetence is important in order to determine whether this pattern correlates with markers of poor prognosis, and for possible modifications to the dobutamine stress protocol to achieve the target heart rate and thus optimise the sensitivity of dobutamine stress echocardiography. In this study we investigated the clinical, haemodynamic, and echocardiographic variables that contribute to chronotropic incompetence during dopamine stress echocardiography in patients with limited exercise capacity who were referred for evaluation of myocardial ischaemia but who were not taking β blocker drugs.

Methods

PATIENT POPULATION

The study population comprised consecutive patients with limited exercise capacity, referred to our imaging laboratory for evaluation of myocardial ischaemia by dopamine stress echocardiography. The patients fulfilled the following criteria:

- Completion of the maximal dobutamine–atropine stress testing protocol or achievement of 85% of the maximum exercise heart rate predicted for age and sex (220 − age (in years) in men; 200 − age in women)
- No β blocker treatment
- The presence of sinus rhythm at baseline electrocardiogram.

By these criteria, patients in whom the test was terminated prematurely before reaching the target heart rate or the maximum dobutamine–atropine dose owing to symptoms or side effects were not included in the study. There were 512 patients who fulfilled these criteria, mean (SD) age was 60 (12) years (313 men and 199 women). All patients gave a
Chronotropic incompetence during dobutamine stress test

Increasing doses of dobutamine were infused through an antecubital vein in three minute stages. The starting dose was 5 µg/kg/min, followed by 10 µg/kg/min, and increasing by 10 µg/kg/min every three minutes to a maximum of 40 µg/kg/min. Atropine (up to 1 mg) was given to patients not achieving 85% of the maximum heart rate predicted for age and sex at the maximum dose of dobutamine, and the dobutamine infusion was continued. The ECG was monitored throughout the dobutamine infusion and recorded each minute. Cuff blood pressure was measured at rest, every three minutes during stress, and at maximum stress. The test was interrupted if there was severe chest pain, ST segment depression > 2 mm, significant ventricular or supraventricular arrhythmia, hypertension (blood pressure ≥ 240/120 mm Hg), systolic blood pressure fall of > 40 mm Hg, or any intolerable side effect regarded as being due to dobutamine. Metoprolol (1–5 mg) was used intravenously to reverse the effects of dobutamine if they persisted.

The test was considered successful if the patient could achieve 85% of the maximum heart rate or when there was an ischaemic end point (angina, ST segment depression, new or worsened wall motion abnormalities), or both. The selection criteria for the study determined that the end point of the test in all patients was the achievement of target heart rate or the administration of the maximum allowable dobutamine–atropine dose. Chronotropic incompetence was defined as the inability to reach 85% of the maximum heart rate predicted for age and sex at the maximum dose of dobutamine (40 µg/kg/min), as used in exercise studies.1-12 This cut off is also used in most laboratories to determine the need for atropine administration in patients with submaximal heart rate at peak dobutamine dose.13-17

STRESS ECHOCARDIOGRAPHY
Echocardiographic images were acquired at rest and during stress and on recovery. The echocardiograms were recorded on video tapes and were also digitised on optical disk and displayed side by side in quad-screen format (Vingmed CFM 800, Vingmed Sound A/S, Horten, Norway) to facilitate the comparison of rest and stress images. The left ventricular wall was divided into 16 segments and scored using a four point scale, where 1 = normal, 2 = hypokinesis, 3 = akinesis, and 4 = dyskinesis. Wall motion score index was derived by dividing the summation of individual score of the 16 segments by 16. The interpretation of images was performed by two experienced observers without knowledge of the patients’ clinical data. In case of disagreement, a majority decision was achieved by a third observer. In our laboratory, the inter- and intraobserver agreement for dobutamine stress echocardiography assessment is 92% and 94%, respectively.13 Ischaemia was defined as new or worsening wall motion abnormalities. If segments that were akinetic at rest became dyskinetic during stress, without improvement with low dose dobutamine, this was not considered to reflect ischaemia, as previously reported.19

CORONARY ANGIOGRAPHY
Coronary angiography was performed within three months of dopamine stress echocardiography in 116 patients. Lesions were quantified as previously described.7 Significant coronary artery disease was defined as diameter stenosis of ≥ 50% in one or more major epicardial arteries.

STATISTICAL ANALYSIS
Unless otherwise specified, data are presented as mean (SD). The χ² test was used to compare differences between proportions. The Student’s t test was used for analysis of continuous data. Stepwise logistic regression models were fitted to identify independent predictors of chronotropic incompetence. Differences were considered significant if the null hypothesis could be rejected at the 0.05 probability level.

Results

HAEMODYNAMIC RESPONSES
The target heart rate was achieved in 316 patients without the need for atropine. The maximum dobutamine dose was 10 µg/kg/min in four patients, 20 µg in 33 patients, 30 µg in 89 patients, and 40 µg in 386 patients. There were 196 patients who failed to achieve the target heart rate at maximum dobutamine dose. These patients comprised the group with chronotropic incompetence. Atropine was given to all of these patients. The target heart rate was reached in 153 of the 196 patients with chronotropic incompetence (78%). Thus chronotropic incompetence refractory to atropine was encountered in 43 patients (22%), representing 8% of the entire population of the study.

The clinical characteristics, drugs, and indications for stress testing in patients with and without chronotropic incompetence are given in table 1. Patients with chronotropic incompetence were significantly younger, more likely to be men and to smoke cigarettes, and had a higher prevalence of previous myocardial infarction and a lower prevalence of hypertension than patients without chronotropic incompetence.

Atropine induced a significant increase in heart rate in patients with chronotropic incompetence (from 112 (20) to 142 (16) beats/min, p < 0.0001). Haemodynamic data in patients with and without chronotropic incompetence are given in table 2. Patients with chronotropic incompetence had a lower resting and peak dobutamine heart rate, a lower resting systolic and diastolic blood pressure, and received a higher dose of dobutamine.

The prevalence of symptoms was similar in patients with and without chronotropic incompetence (table 3). Premature ventricular
Table 1  Clinical features of patients with and without chronotropic incompetence during dobutamine stress echocardiography

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Yes (n = 196)</th>
<th>No (n = 316)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (mean (SD))</td>
<td>56 (13)</td>
<td>62 (11)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Male</td>
<td>145 (74)</td>
<td>168 (53)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>108 (55)</td>
<td>131 (41)</td>
<td>&lt; 0.005</td>
</tr>
<tr>
<td>History of heart failure</td>
<td>22 (11)</td>
<td>52 (10)</td>
<td>0.1</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>56 (29)</td>
<td>126 (40)</td>
<td>0.04</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>27 (14)</td>
<td>42 (13)</td>
<td>0.9</td>
</tr>
<tr>
<td>Smoking</td>
<td>78 (40)</td>
<td>94 (30)</td>
<td>0.04</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>40 (20)</td>
<td>60 (19)</td>
<td>0.9</td>
</tr>
<tr>
<td>Height (cm) (mean (SD))</td>
<td>173 (9)</td>
<td>169 (10)</td>
<td>&lt; 0.0005</td>
</tr>
<tr>
<td>Body weight (kg) (mean (SD))</td>
<td>75 (13)</td>
<td>74 (14)</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Table 2  Haemodynamic data in patients with and without chronotropic incompetence during dobutamine stress echocardiography

<table>
<thead>
<tr>
<th>Haemodynamic and stress test variables</th>
<th>Yes (n = 196)</th>
<th>No (n = 316)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR at rest (beats/min)</td>
<td>71 (12)</td>
<td>78 (13)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>HR at peak dobutamine (beats/min)</td>
<td>112 (21)</td>
<td>133 (16)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>HR increment from rest to peak dobutamine dose</td>
<td>41 (8)</td>
<td>55 (9)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Systolic BP at rest (mm Hg)</td>
<td>127 (21)</td>
<td>137 (23)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Systolic BP at peak dobutamine (mm Hg)</td>
<td>135 (26)</td>
<td>139 (28)</td>
<td>0.3</td>
</tr>
<tr>
<td>Diastolic BP at rest (mm Hg)</td>
<td>73 (13)</td>
<td>77 (13)</td>
<td>&lt; 0.005</td>
</tr>
<tr>
<td>Diastolic BP at peak dobutamine (mm Hg)</td>
<td>69 (13)</td>
<td>71 (15)</td>
<td>0.6</td>
</tr>
<tr>
<td>Systolic BP drop &gt; 20 mm Hg</td>
<td>30 (15%)</td>
<td>59 (19%)</td>
<td>0.3</td>
</tr>
<tr>
<td>Systolic BP drop &gt; 40 mm Hg</td>
<td>9 (5%)</td>
<td>12 (4%)</td>
<td>0.7</td>
</tr>
<tr>
<td>Maximum dobutamine dose (µg/kg/min)</td>
<td>40 (21%)</td>
<td>59 (19%)</td>
<td>0.5</td>
</tr>
<tr>
<td>ST segment depression</td>
<td>30 (15%)</td>
<td>43 (14%)</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Table 3  Symptoms and arrhythmias in patients with and without chronotropic incompetence during dobutamine stress echocardiography

<table>
<thead>
<tr>
<th>Symptoms/arrhythmias</th>
<th>Yes (n = 196)</th>
<th>No (n = 316)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>14 (7)</td>
<td>8 (3)</td>
<td>0.6</td>
</tr>
<tr>
<td>flushing</td>
<td>1 (0.5)</td>
<td>4 (1.2)</td>
<td>0.2</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7 (4)</td>
<td>4 (1.3)</td>
<td>0.9</td>
</tr>
<tr>
<td>Anxiety</td>
<td>4 (2)</td>
<td>5 (1.5)</td>
<td>0.7</td>
</tr>
<tr>
<td>Chills</td>
<td>10 (5)</td>
<td>14 (4)</td>
<td>0.1</td>
</tr>
<tr>
<td>Headache</td>
<td>7 (4)</td>
<td>17 (5)</td>
<td>0.1</td>
</tr>
<tr>
<td>Symptomatic hypotension</td>
<td>1 (0.5)</td>
<td>2 (0.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>Premature atrial contractions</td>
<td>18 (9)</td>
<td>18 (6)</td>
<td>0.1</td>
</tr>
<tr>
<td>Premature ventricular contractions</td>
<td>76 (39)</td>
<td>91 (29)</td>
<td>0.02</td>
</tr>
<tr>
<td>Supraventricular tachycardia</td>
<td>4 (2)</td>
<td>11 (3)</td>
<td>0.3</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>0</td>
<td>3 (1)</td>
<td>0.2</td>
</tr>
<tr>
<td>Ventricular tachycardia ≤ 10 beats</td>
<td>7 (4)</td>
<td>9 (3)</td>
<td>0.6</td>
</tr>
<tr>
<td>Ventricular tachycardia &gt; 10 beats</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Values are n (%).
SEX DIFFERENCES

There was no significant difference between men and women with respect to age (60 (12) v 62 (13) years, p = 0.3) or peak heart rate (121 (22) v 116 (20) beats/min, p = 0.2, respectively). Women received a lower maximum dose of dobutamine than men (34.6 (7.5) v 37.9 (5) μg/kg/min, p << 0.001). In the 386 patients who received the maximum dobutamine dosage (40 μg/kg/min), chronotropic incompetence was detected in 145 of 263 men (55%) and 51 of 123 women (41%) (p < 0.05). A target heart rate of 210 − age in women was identified as the cut off point that resulted in an equal prevalence of chronotropic incompetence (55%) in men and women.

Discussion

To our knowledge, this is the first study to evaluate the clinical, haemodynamic, and echocardiographic characteristics of patients with chronotropic incompetence during dobutamine stress echocardiography. Unlike the exercise stress test, the heart rate response during the dobutamine stress test is independent of the functional capacity of the patient. We included only patients who could complete the standard dobutamine stress protocol or reached the target heart rate. Therefore chronotropic incompetence in this study represents an intrinsic failure to achieve the target heart rate rather than being a result of premature termination of the test. Additionally, we excluded patients receiving β blockers to avoid the confounding effect of these drugs on the heart rate response to dobutamine.

PREDICTORS OF CHRONOTROPIC INCOMPETENCE

Independent predictors of chronotropic incompetence during dobutamine stress echocardiography using a multivariate analysis model were a lower baseline heart rate, a younger age, and male sex. A lower resting heart rate might have contributed to chronotropic incompetence because in this case a larger increment of heart rate is necessary to achieve the target heart rate. However, patients with chronotropic incompetence also had a lower increment of heart rate from rest to peak dobutamine dose despite receiving a higher dose of dobutamine and despite being younger. One explanation is that patients with chronotropic incompetence had intrinsically lower sinus node activity at rest and in response to dobutamine infusion, though they had no manifest clinical disease of the sinoatrial node. Another explanation is that a higher resting heart rate represents a state of a higher sympathetic than parasympathetic activity or a state of increased sympathetic reactivity of the heart. Therefore patients with a higher baseline heart rate would be more responsive to dobutamine infusion. Supporting this theory is our finding of a higher baseline systolic and diastolic blood pressure in the group without chronotropic incompetence, which is in favour of a higher sympathetic than parasympathetic tone or increased sympathetic responsiveness in patients with than without an adequate chronotropic response.

A younger age was an independent predictor of chronotropic incompetence. The increase in myocardial contractility during dobutamine infusion may be associated with reflex activation of parasympathetic tone, which in turn would reduce the chronotropic response to dobutamine, as has been suggested before. Such an effect may be attenuated in elderly people owing to the reduction in vagal activity that occurs with aging. Another explanation for the age difference is that the values used to define a target heart rate in relation to age are derived from exercise rather than from a dobutamine stress test. The cardiovascular response to exercise is different from the response to dobutamine infusion, so sex and age related heart rate response to exercise may not necessarily apply to dobutamine. The same factors may explain our finding of a higher prevalence of chronotropic incompetence in men, as the calculated target heart rate for women is less than for men of the same age.

Another factor that may contribute to the age and sex related differences between patients with and without chronotropic incompetence is the difference in drug pharmacokinetics. Healthy elderly subjects have been shown to have increased sensitivity to dobutamine. In our study, there was no significant difference between men and women with respect to age and maximum dobutamine heart rate despite the fact that women received a significantly smaller dose of dobutamine. This shows that women have a greater heart rate response to dobutamine than men. The presence of age and sex difference between patients with and without chronotropic incompetence warrants a study of the heart rate response to dobutamine in normal individuals related to age and sex to derive a formula for target heart rate during a dobutamine stress test rather than using an arbitrary formula derived from the exercise stress test. In this study, the use of the smaller difference in target heart rate between men and women (220 − age in men v 200 − age in women) resulted in a similar prevalence of chronotropic incompetence in men and women. However, this analysis only included patients who received the maximum dobutamine dose, to avoid the confounding effect of including women in whom the test was terminated at lower dobutamine dose on achieving the target heart rate defined as 200 − age.

Ischaemia was not predictive of chronotropic incompetence, although previous studies described attenuated baroreceptor sensitivity and reduced efferent cardiac sympathetic activity during experimental acute myocardial ischaemia. This could be explained by a reduction in the prevalence of ischaemia in patients with impaired chronotropic response, balancing the bradycardia inducing effect of ischaemia. However, we found a trend to a higher prevalence of ischaemia in the posterolateral circulation in patients with chronotropic incompetence, which may be related to the higher prevalence of myocardial...
infarction and wall motion abnormalities in these patients.

CHRONOTROPIC INCOMPETENCE REFRACTORY TO ATROPINE
Refactoriness to atropine occurred in 22% of patients with chronotropic incompetence at the maximum dobutamine dose. These patients had a lower heart rate at maximum dobutamine dose, which implies that such patients may require more than 1 mg of atropine to achieve the target heart rate. The mean age of these patients was younger, which may be explained by the greater vagal tone in the young and therefore the need for a larger dose of atropine. A greater height was also predictive of refractory chronotropic incompetence. This shows that atropine dose should be adjusted to the body surface area rather than being a fixed value in all patients.

COMPARISON WITH PREVIOUS STUDIES
Attenhofer et al reported paradoxical sinus deceleration during dopamine stress echocardiography in 8% of patients who underwent coronary angiography.

The Framingham study, chronotropic incompetence during exercise was detected in 21% of participants. In contrast with our findings, patients with chronotropic incompetence were older and had a higher resting blood pressure. In agreement with our findings, however, patients with chronotropic incompetence were more likely to smoke cigarettes and had a lower resting heart rate. However, the Framingham study did not evaluate the influence of sex or left ventricular wall motion abnormalities, as that study did not include women or patients with previous myocardial infarction. Previous studies have shown that patients with heart failure have chronotropic incompetence during exercise. Although patients with chronotropic incompetence in our study had a higher prevalence of myocardial infarction and resting wall motion abnormalities, there was no difference with respect to a history of congestive heart failure. Heart rate response is a function of exogenous sympathetic stimulation during dobutamine infusion and therefore the response may differ during exercise, as it is dependent on endogenous sympathetic release and responsiveness.

LIMITATIONS OF THE STUDY
Coronary angiography was performed in only 23% of patients. Therefore, the correlation between chronotropic incompetence and angiographic findings was not established in all patients. This would have been necessary to evaluate the trend towards an increased prevalence of left circumflex coronary artery disease in patients with chronotropic incompetence. Although our study excluded patients receiving beta blockers, some were receiving vasoactive drugs such as calcium channel blockers, nitrates, and angiotensin converting enzyme inhibitors, which may modify the sympathetic tone and influence the chronotropic response. However, none of these drugs was independently predictive of chronotropic incompetence during dobutamine stress echocardiography.

Finally our study evaluated the clinical, haemodynamic, and echocardiographic correlates of chronotropic incompetence, but their prognostic significance remains to be evaluated.

SUMMARY AND CONCLUSIONS
Although chronicotropic incompetence during dobutamine stress echocardiography correlated with variables known to be associated with an increased risk of adverse prognosis, such as previous myocardial infarction, smoking, and resting wall motion abnormalities, chronicotropic incompetence was associated with other variables linked with a better prognosis, such as younger age, a lower preva-
Chronicotopic incompetence during dobutamine stress test


The functional significance of chronotropic incompetence during dobutamine stress test

A Elhendy, R T van Domburg, J J Bax, P R Nierop, M L Geleijnse, M M Ibrahim and J R T C Roelandt

Heart 1999 81: 398-403
doi: 10.1136/hrt.81.4.398

Updated information and services can be found at:
http://heart.bmj.com/content/81/4/398

These include:

References
This article cites 24 articles, 6 of which you can access for free at:
http://heart.bmj.com/content/81/4/398#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8839)
- Clinical diagnostic tests (4778)
- Echocardiography (2126)
- Acute coronary syndromes (2742)
- Hypertension (3004)
- Tobacco use (635)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/